NU SKIN ENTERPRISES, INC. - 10-Q Summary (Q2 2026)
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2026. Nu Skin Enterprises, Inc. operates as a holding company with primary operations in the Nu Skin beauty and wellness direct selling business and the Rhyz strategic investment arm. The company reports across nine segments: seven geographic Nu Skin regions and two Rhyz segments (Manufacturing and Other).
Key Financial Metrics
| Metric | Q2 2026 | Q2 2025 | YTD 2026 | YTD 2025 |
|---|---|---|---|---|
| Revenue | $320.1 million | $386.1 million | $640.7 million | $750.6 million |
| Gross Profit | $218.3 million (68.2%) | $265.7 million (68.8%) | $432.8 million (67.5%) | $512.7 million (68.3%) |
| Operating Income (Loss) | $(59.3) million | $30.8 million | $(55.3) million | $20.9 million |
| Net Income (Loss) | $(249.8) million | $21.1 million | $(248.0) million | $128.6 million |
| Diluted EPS | $(5.14) | $0.43 | $(5.12) | $2.59 |
| Cash from Operations | N/A | N/A | $6.7 million | $36.2 million |
| Cash & Equivalents | $189.6 million | N/A | N/A | N/A |
| Total Debt | $213.7 million | N/A | N/A | N/A |
Note: Debt consists of $20.0 million current portion and $193.7 million long-term portion as of June 30, 2026.
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 17.1% in Q2 and 14.6% YTD compared to the prior year, driven by macroeconomic challenges, reduced consumer spending, and declines in Customers (-14%), Paid Affiliates (-8%), and Sales Leaders (-9%).
- Impairment Charges: A significant non-cash goodwill impairment charge of $78.9 million was recorded in Q2 2026 related to the Rhyz Manufacturing reporting unit due to declining stock price and forecast revisions. Additionally, a $1.8 million impairment was recorded in Q1 2026 for the wind-down of the BeautyBio business.
- Tax Provision Spike: The company established a $167.5 million valuation allowance against U.S. deferred tax assets in Q2 2026, resulting in an effective tax rate of (295.4%) for the quarter. This was driven by cumulative losses in the U.S. entity over the past three years.
- Debt Restructuring: In March 2026, the company entered a new Credit Agreement, replacing the 2022 agreement. The new facility includes a $175 million term loan and a $75 million revolving credit facility.
Guidance, Outlook, and Risks
- Strategic Shifts: Management is shifting the Prysm iO platform strategy from device placement to an assessment model to improve in-person engagement. The full market opening in India is now targeted for the first half of 2027.
- Cost Management: G&A expenses decreased due to lower incentive compensation and software contract reductions. However, the company anticipates approximately $5.0 million in incremental selling expenses in Q3 2026 due to a global event in Japan and $5.0 million in transition costs related to organizational realignment.
- Liquidity: Cash and cash equivalents decreased to $189.6 million. The company maintains $137.3 million available under its stock repurchase plan, though no shares were repurchased in Q2 2026. Quarterly dividends of $0.06 per share continue.
- Risks: Key risks include continued macroeconomic headwinds, foreign currency fluctuations, regulatory challenges in direct selling markets, and the realization of deferred tax assets.
Investor Verification Checklist
- Valuation Allowance: Verify the sustainability of the $167.5 million tax valuation allowance and its impact on future effective tax rates.
- Goodwill Impairment: Assess the long-term viability of the Rhyz Manufacturing segment following the $78.9 million write-down.
- India Expansion: Monitor progress on the India market entry, now delayed to H1 2027, and associated pre-market costs.
- Debt Covenants: Confirm continued compliance with the new Credit Agreement covenants (leverage ratio max 2.25:1).
- Segment Performance: Review the specific drivers of revenue decline in South Korea (-24.8%) and Americas (-18.1%) versus stabilization in Hong Kong/Taiwan.